<DOC>
	<DOCNO>NCT01667380</DOCNO>
	<brief_summary>This observational study evaluate use efficacy Mircera ( methoxy polyethylene glycol-epoetin beta ) anemia patient chronic kidney disease ( CKD ) stage III-IV dialysis CKD stage V dialysis . Patients follow 12 month treatment .</brief_summary>
	<brief_title>An Observational Study Mircera Patients With Chronic Renal Anemia Dialysis ( CKD Stage V ) Not Dialysis ( CKD Stage III-IV )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Patients chronic renal anemia stage IIIIV CKD dialysis , opinion treat physician , expect baseline require dialysis within 12 month Patients chronic renal anemia stage V CKD dialysis No contraindication ESA treatment Uncontrolled hypertension Hypersensitivity active substance excipients Mircera ESAs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>